IMMUCELL CORP /DE/ (ICCC) earnings date, results and what the price requires
Nasdaq · SEC CIK 0000811641 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Sep 30, 2026 | Oct 13, 2026 | Announced; figures arrive with the 10-Q | — | — | Filing |
| Jun 30, 2026 | Aug 13, 2026 | $7.2M | $1.8M | $0.20 | Filing |
| Mar 31, 2026 | May 14, 2026 | $10.4M | $1.9M | $0.21 | Filing |
| Dec 31, 2025 | Mar 4, 2026 | $7.6M | $-2.8M | $-0.32 | Filing |
| Sep 30, 2025 | Nov 13, 2025 | $5.5M | $-139,748 | $-0.02 | Filing |
| Jun 30, 2025 | Aug 14, 2025 | $6.4M | $501,880 | $0.06 | Filing |
| Mar 31, 2025 | May 14, 2025 | $8.1M | $1.4M | $0.16 | Filing |
| Dec 31, 2024 | Jan 10, 2025 | $7.8M | $514,184 | $0.09 | Filing |
| Sep 30, 2024 | Nov 13, 2024 | $6.0M | $-701,690 | $-0.09 | Filing |
What would IMMUCELL CORP /DE/ have to report for its valuation to change?
At $10.75, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 67.4% a year, to $0.92. On that path the next quarter needs diluted EPS near $-0.03, against $-0.02 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 67.4% | 67.4% |
| EPS needed in final year | $0.92 | $0.92 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ICCC goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.